N-环己基-3-溴苯磺酰胺 | 871269-10-2

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 磺胺类药及增效剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-环己基-3-溴苯磺酰胺
• 中文别名: N-环己基3-溴苯磺酰胺
• 英文名称: 3-bromo-N-cyclohexylbenzenesulfonamide
• 英文别名: N-Cyclohexyl 3-bromobenzenesulfonamide
• CAS: 871269-10-2
• 化学式: C₁₂H₁₆BrNO₂S
• mdl: MFCD07363823
• 分子量: 318.235
• InChiKey: MLUYYAINRSPCFT-UHFFFAOYSA-N

物化性质

• 沸点：
  423.7±47.0 °C(Predicted)
• 密度：
  1.50±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319
• 储存条件：
  存储条件：2-8°C，避光干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
N-Cyclohexyl 3-bromobenzenesulfonamide
Product Name:
Synonyms: N-Cyclohexyl 3-bromophenylsulfonamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P302+P352: IF ON SKIN: Wash with soap and water
P321: Specific treatment (see on this label)
P405: Store locked up

---

Section 3. Composition/information on ingredients.
N-Cyclohexyl 3-bromobenzenesulfonamide
Ingredient name:
CAS number: 871269-10-2

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H16BrNO2S
Molecular weight: 318.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-环己基-3-溴苯磺酰胺 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 N-cyclohexyl-3-(6-fluoro-1H-indazol-3-yl)benzenesulfonamide
  参考文献：
  名称：

  Rational Design, Optimization, and Biological Evaluation of Novel MEK4 Inhibitors against Pancreatic Adenocarcinoma

  摘要：

  DOI：

  10.1021/acsmedchemlett.1c00376
• 作为产物：
  描述：

  3-溴苯磺胺 、 环己甲酸 在 噻吩-2-甲酸亚铜(I) 、 [4,4''-双（1,1-二甲基乙基）-2,2''-联吡啶-κN，κN]双[5-氟-2-（5-甲基-2-吡啶基-κN）苯基-κC六氟磷酸铱 、 2-叔丁基-1,1,3,3-四甲基胍 、 4,7-二苯基-1,10-菲罗啉 、 iodomesitylene diacetate 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 以50%的产率得到N-环己基-3-溴苯磺酰胺
  参考文献：
  名称：

  通过双铜和光氧化还原催化进行脱羧 sp3 C-N 偶联

  摘要：

  在过去的三十年中，利用钯、铜或镍催化构建 sp2 碳氮 (C-N) 键的方法的开发取得了相当大的进展1,2。然而，结合烷基底物形成sp3 C-N键仍然是交叉偶联化学领域的主要挑战之一。在这里，我们证明铜催化和光氧化还原催化的协同组合可以提供一个通用平台来应对这一挑战。该交叉偶联系统使用天然丰富的烷基羧酸和市售的氮亲核试剂作为偶联伙伴。它适用于各种伯、仲和叔烷基羧酸（通过碘鎓活化），以及大量氮亲核试剂：氮杂环、酰胺、磺酰胺和苯胺可以进行 C-N 偶联，提供 N-在室温下和短时间内（五分钟到一小时），烷基产品的效率从良好到优异。我们证明，这种 C-N 偶联方案使用含有多个胺基的底物进行高区域选择性，并且还可以应用于复杂的药物分子，从而能够快速构建分子复杂性和生物活性药物的后期功能化。铜催化和光氧化还原催化的结合在快速、室温偶联方案中形成 sp3 C-N 键，具有高效率和区域选择性以及广泛的底物范围。

  DOI：

  10.1038/s41586-018-0234-8

文献信息

• SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS
  申请人：Scott Ian L.

  公开号：US20100093865A1

  公开（公告）日：2010-04-15

  Provided are sulphur-linked compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.

  提供的是硫连接化合物、其药物组合物以及使用所述化合物和组合物治疗眼科疾病和障碍的方法，例如年龄相关的黄斑变性和斯达加特病。
• Synthesis and biological evaluation of novel 2,4-dianilinopyrimidine derivatives as potent dual janus kinase 2 and histone deacetylases inhibitors
  作者：Haiping Zhou、Junhao Jiang、Jinyu Lu、Dongzhi Ran、Zongjie Gan

  DOI：10.1016/j.molstruc.2021.132200

  日期：2022.4

  deacetylases (HDAC) inhibitor in combination with janus kinase (JAK) inhibitor could exhibit synergistically anti-proliferative effects in cancer treatment. Herein, we presented a novel series of 2,4-dianilinopyrimidine derivatives, which could simultaneously inhibit JAK2 and HDAC1. Among which, 7l was found to be the most potent compound and displayed balanced inhibitory activity against HDAC1 (IC50 = 1

  在单个分子中双重或多重靶向抑制致癌靶点可能是药物组合的替代方法。先前的研究表明，组蛋白去乙酰化酶 (HDAC) 抑制剂与 janus 激酶 (JAK) 抑制剂联合使用可在癌症治疗中发挥协同抗增殖作用。在此，我们提出了一系列新型 2,4-二苯氨基嘧啶衍生物，可同时抑制 JAK2 和 HDAC1。其中，7l被发现是最有效的化合物，并分别显示出对 HDAC1 (IC 50  = 1.9 nM) 和 JAK2 (IC 50  = 0.5 nM) 的平衡抑制活性。7升还对测试的癌细胞系（A549、HepG-2、MDA-MB-231 和 Jurkat）显示出良好的抗增殖活性。此外，流式细胞术分析表明，7l以剂量依赖性方式诱导细胞凋亡和细胞周期停滞，对7l机制的深入了解表明，它可以降低 STAT-3 的磷酸化并促进组蛋白乙酰化。总之，这些结果共同表明7l将是一个有前途的主要候选物，值得进一步研究和开发。
• Bi-aryl meta-pyrimidine inhibitors of kinases
  申请人：Noronha Glenn

  公开号：US20070259904A1

  公开（公告）日：2007-11-08

  The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.

  本发明提供了具有一般结构（A）的联苯基间吡嘧啶化合物。本发明的吡嘧啶化合物能够抑制激酶，如Jak激酶家族成员以及其他特定的受体和非受体激酶。
• 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
  申请人：HARRIS J. Keith

  公开号：US20070265278A1

  公开（公告）日：2007-11-15

  The present invention is directed to a compound of Formula (XVI): (please replace Formula (I) with Formula (XVI) as shown below) wherein R, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and n are as defined herein, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutically acceptable prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of the prodrug, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (XVI) in admixture with a pharmaceutically acceptable carrier, a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (XVI).

  本发明涉及一种化合物，其化学式为（XVI），其中R、R2、R3、R4、R5、R6、R7和n如本文所定义，或其药学上可接受的盐、水合物或溶剂化物，其药学上可接受的前药，或其药学上可接受的前药的盐、水合物或溶剂化物，以及一种制剂，其中该制剂包含一种或多种符合化学式（XVI）的化合物的药学有效量，与药学上可接受的载体混合，一种治疗患有PGD2介导的疾病的患者的方法，包括但不限于，过敏性疾病（如过敏性鼻炎、过敏性结膜炎、特应性皮炎、支气管哮喘和食物过敏）、全身性肥大细胞增多症、伴随全身性肥大细胞活化的疾病、过敏性休克、支气管收缩、支气管炎、荨麻疹、湿疹、伴随瘙痒的疾病（如特应性皮炎和荨麻疹）、疾病（如白内障、视网膜脱离、炎症、感染和睡眠障碍），这些疾病是由于瘙痒所伴随的行为（如搔抓和打击）引起的，炎症、慢性阻塞性肺疾病、缺血再灌注损伤、脑血管意外、慢性类风湿性关节炎、胸膜炎、溃疡性结肠炎等，通过向该患者投与符合化学式（XVI）的化合物的药学有效量。
• Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases
  申请人：Noronha Glenn

  公开号：US20090275582A1

  公开（公告）日：2009-11-05

  The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.

  本发明提供具有一般结构（A）的双芳基间位嘧啶化合物。本发明的嘧啶化合物能够抑制激酶，如Jak激酶家族的成员，以及各种其他特定的受体和非受体激酶。